Athira Pharma reports Q3 net loss of $20.2M; LIFT-AD interim analysis supports continuation

LeonaBio, Inc.

2022-Q3 EPS reported -$1.74

Net loss of $20.2M ($0.53/shr) for Q3 2022 vs $15.7M ($0.42) in Q3 2021; cash $260.0M at Sep 30, 2022.
R&D expenses $17.0M (up from $10.7M YoY) driven by clinical trial and personnel costs.
LIFT-AD interim analysis supports continuation; DMC determined <150 more patients needed for adequate power on primary endpoint.
Expects LIFT-AD enrollment completion mid-2023; topline data early 2024.
ACT-AD Phase 2 data showed statistically significant improvement in NfL biomarker in patients not on background therapy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LeonaBio, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the third quarter ended September 30, 2022 and reviewed recent clinical and corporate updates.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.